## Introduction
Patient-Derived Xenograft (PDX) models are a cornerstone of modern translational medicine, offering a high-fidelity platform to study human cancers in a preclinical setting. These models bridge the critical gap between laboratory research and clinical practice by closely recapitulating the biological complexity of a patient's original tumor, an authenticity often lost in traditional cell-line-based systems. By preserving the genetic landscape, [cellular heterogeneity](@entry_id:262569), and architectural features of the primary cancer, PDX models serve as powerful tools for evaluating therapeutic efficacy, investigating resistance mechanisms, and discovering predictive biomarkers.

This article provides a comprehensive guide to understanding and utilizing PDX models. The first chapter, **"Principles and Mechanisms,"** delves into the core definition of PDX models, their biological fidelity, and the critical methodological choices involved in their establishment, from [host selection](@entry_id:203952) to implantation techniques. The second chapter, **"Applications and Interdisciplinary Connections,"** explores their pivotal role in drug development, [biomarker discovery](@entry_id:155377), and the emerging fields of [personalized medicine](@entry_id:152668) and [immuno-oncology](@entry_id:190846). Finally, the **"Hands-On Practices"** section offers practical exercises for applying key concepts, such as dose conversion and efficacy analysis. Together, these sections equip researchers with the foundational knowledge needed to effectively design, execute, and interpret studies using these powerful preclinical tools.

## Principles and Mechanisms

### Defining the Patient-Derived Xenograft Model

Patient-Derived Xenograft (PDX) models represent a cornerstone of modern translational oncology, serving as high-fidelity biological surrogates for human cancers in a preclinical setting. A PDX is established by the direct implantation of fresh, viable tumor tissue from a patient into a severely immunodeficient mouse. This fundamental procedure, which bridges the gap between clinical oncology and laboratory research, is predicated on a set of core principles that distinguish PDX models from other preclinical systems.

#### The Criterion of Authenticity: Preserving Translational Continuity

The primary value of a PDX model lies in its ability to maintain **translational continuity** with the patient's original tumor. This means the model should recapitulate the key biological features of the cancer it is derived from, including its genetic landscape, histopathological architecture, and, most importantly, its [cellular heterogeneity](@entry_id:262569). To achieve this, the standard and most authentic method for establishing a PDX involves the direct engraftment of surgically resected tumor fragments with minimal *ex vivo* manipulation.

A critical methodological choice distinguishes an authentic PDX from a related, but distinct, model. In some workflows, a patient's tumor may be dissociated into single cells and then expanded for several passages in two-dimensional ($2$D) monolayer culture before being implanted into a host mouse. While the resulting tumor is technically "patient-derived" in origin (verifiable, for example, by Short Tandem Repeat profiling), the intermediate culture step imposes a strong, non-physiological selective pressure. The artificial environment of a plastic dish and culture medium favors the proliferation of a small subset of aggressive clones that are adapted to anchorage-dependent growth, while clones that are quiescent, dependent on specific stromal interactions, or less adapted to the culture medium are lost. This process acts as a severe [population bottleneck](@entry_id:154577) that fundamentally alters the clonal composition and phenotypes of the tumor, breaking the translational continuity that is the central goal of the PDX approach. Therefore, the explicit avoidance of intermediate *in vitro* culture is a defining criterion for an authentic PDX model, ensuring that the engrafted tissue most closely represents the complex ecosystem of the original patient tumor [@problem_id:5039632].

#### A Comparative Analysis of Preclinical Cancer Models

The unique characteristics of PDX models are best understood by comparing them to other commonly used preclinical systems: Cell Line-Derived Xenografts (CDX), syngeneic models, and Patient-Derived Organoids (PDOs). This comparison can be structured along three key axes: the source of the tumor, the preservation of the [tumor microenvironment](@entry_id:152167) (TME), and the host context [@problem_id:5039636].

*   **Patient-Derived Xenograft (PDX):**
    *   **Source:** Intact fragments of a human patient's tumor.
    *   **Microenvironment:** Initially preserves the native 3D architecture, intra-tumor heterogeneity, and human stromal components (e.g., fibroblasts, extracellular matrix). However, over serial mouse-to-mouse transfers (passages), this human stroma is progressively replaced by murine stroma.
    *   **Host Context:** An immunodeficient mouse, which prevents rejection of the foreign human tissue. This lack of a competent immune system is a major limitation for studying immunotherapies unless specialized "humanized" mouse models are used.

*   **Cell Line-Derived Xenograft (CDX):**
    *   **Source:** Established, clonally-selected human tumor cell lines that have been cultured *in vitro* for extended periods.
    *   **Microenvironment:** Lacks the original tumor architecture and heterogeneity. The tumor that forms is a relatively homogeneous mass of cancer cells, and its entire supporting stroma (vasculature, fibroblasts) is of mouse origin from the outset.
    *   **Host Context:** An immunodeficient mouse.

*   **Syngeneic Mouse Model:**
    *   **Source:** A mouse tumor cell line.
    *   **Host Context:** An immunocompetent mouse of the same inbred strain (genetically identical, or syngeneic). This genetic match prevents immune rejection.
    *   **Microenvironment:** The entire system—tumor cells, stroma, and a fully functional [adaptive immune system](@entry_id:191714)—is of murine origin. This makes syngeneic models the primary tool for studying tumor-immune interactions and immunotherapies, albeit in a purely mouse context.

*   **Patient-Derived Organoid (PDO):**
    *   **Source:** Cells or tissue fragments from a patient's tumor.
    *   **Microenvironment:** An *ex vivo* 3D culture system where cells are grown in an extracellular matrix gel. It preserves the epithelial architecture and clonal heterogeneity of the parent tumor to some extent but completely lacks a systemic host environment, meaning there is no vasculature and no native, circulating immune cell compartment unless these are explicitly engineered into the co-culture system.
    *   **Host Context:** No host; it is an *in vitro* system.

In summary, PDX models occupy a unique niche. Compared to CDX models, they offer far superior preservation of the original tumor's heterogeneity and architecture. Compared to syngeneic models, they use human, rather than mouse, tumor cells, which is critical for studying human-specific [cancer genetics](@entry_id:139559) and targeted therapies. And compared to organoids, they provide an *in vivo* context with a physiological vascular supply and systemic host interactions, albeit with the significant caveat of a murine stroma and an absent human immune system [@problem_id:5039636] [@problem_id:5039698].

### The Biological Fidelity of PDX Models

The rationale for prioritizing PDX models in many translational studies stems from their unparalleled ability, among *in vivo* systems, to recapitulate the complex biology of a patient's tumor. This fidelity has profound implications for the reliability of preclinical drug testing.

#### Preserving the Tumor Ecosystem

A solid tumor is a complex ecosystem where cancer cells exist in a spatially structured community, subject to varying selection pressures. In a 3D tumor mass, cells are exposed to gradients of oxygen, nutrients, and growth factors that are a function of their distance from the nearest blood vessel—a phenomenon governed by **diffusion-limited transport**. This creates distinct micro-environmental niches that support diverse cellular phenotypes. For instance, cells in hypoxic (low-oxygen) regions may enter a state of quiescence (a reversible exit from the cell cycle), rendering them resistant to conventional chemotherapies that target rapidly dividing cells. By implanting intact tumor fragments, PDX models maintain this 3D architecture and its associated spatial gradients. This preserves these diverse cell states, including quiescent and hypoxic subclones that would be rapidly outcompeted and lost in the uniform, high-nutrient environment of a 2D monolayer culture. This preservation allows for more faithful modeling of responses to cytotoxic agents and provides a physical barrier to [drug delivery](@entry_id:268899), enabling the study of drug penetration—an aspect entirely absent in cell culture [@problem_id:5039698].

Furthermore, the mechanical properties of the tumor's extracellular matrix (ECM) provide critical cues that regulate [cell behavior](@entry_id:260922) through a process called **mechanotransduction**. Signaling pathways such as the **YAP/TAZ** pathway are highly sensitive to matrix stiffness and topology, influencing cell proliferation and drug sensitivity. PDX models, by retaining a complex ECM architecture, allow these physiologically relevant signaling pathways to function. In contrast, the unnaturally rigid and flat surface of a culture dish provides aberrant mechanical signals that dysregulate these pathways, further distancing cultured cells from their *in vivo* counterparts [@problem_id:5039698]. By avoiding the harsh selection and artificial environment of cell culture, PDX models reduce population bottlenecks and preserve the original clonal diversity of the tumor. This maintenance of interclonal variability in drug targets and resistance mechanisms is a primary reason for the higher concordance of drug responses between PDX models and patients [@problem_id:5039698].

### Key Methodological Considerations in PDX Establishment and Use

The successful creation and interpretation of PDX models depend on several critical methodological choices, from the host animal to the preparation and location of the tumor implant.

#### The Host: A Spectrum of Immunodeficiency

The transplantation of human tissue into a mouse (a xenograft) would normally trigger a powerful immune response leading to [graft rejection](@entry_id:192897). To prevent this, PDX models require the use of immunodeficient mouse strains. These strains carry specific genetic mutations that cripple different components of the immune system. The choice of strain influences the probability of successful tumor engraftment and the types of biological questions that can be addressed. The level of immunodeficiency exists on a spectrum, with more severely compromised hosts generally permitting higher rates of engraftment [@problem_id:5039637].

*   **Nude Mice:** These mice have a mutation in the **$FOXN1$** gene, resulting in thymic aplasia (an absent or non-functional thymus). This leads to a profound deficiency in T lymphocytes, a key component of the [adaptive immune system](@entry_id:191714). However, nude mice retain functional B lymphocytes, Natural Killer (NK) cells, and other innate immune components. Their engraftment rates for PDX are modest.
*   **SCID Mice:** Severe Combined Immunodeficiency (SCID) mice carry a mutation in the **$Prkdc$** gene, which encodes a protein kinase essential for V(D)J recombination. This process is required to generate functional antigen receptors on both T and B cells. Consequently, SCID mice lack both mature T and B lymphocytes, representing a more severe immunodeficiency than that of nude mice. They still possess functional NK cells.
*   **NOD/SCID Mice:** These mice combine the $Prkdc^{scid}$ mutation with the Non-Obese Diabetic (NOD) genetic background. The NOD background confers additional defects in the [innate immune system](@entry_id:201771), including deficiencies in the complement system, reduced macrophage function, and decreased NK cell activity. This further suppression of host immunity leads to higher PDX engraftment rates compared to standard SCID mice.
*   **NSG (NOD scid gamma) Mice:** Representing one of the most severely immunodeficient strains available, NSG mice build upon the NOD/SCID background by adding a null mutation in the **$IL2RG$** gene. This gene encodes the [common gamma chain](@entry_id:204728) ($\gamma_c$), a shared and essential component for the receptors of several key cytokines, including Interleukin-2 (IL-2), IL-7, and IL-15. The consequences of this mutation are profound:
    *   Disruption of **IL-15 signaling** abrogates the development and survival of NK cells, eliminating a major cellular barrier to xenograft engraftment.
    *   Disruption of **IL-7 signaling** further cripples any potential for lymphoid progenitor development, creating a more stringent T and B cell deficiency than the $scid$ mutation alone.
    The combined absence of T cells, B cells, and NK cells, along with the innate immune defects of the NOD background, makes NSG mice highly permissive hosts for the engraftment of human tissues, including tumors and hematopoietic stem cells. This property has made NSG mice the gold standard for creating "humanized mice," where a human immune system is reconstituted alongside the human tumor, enabling the study of human-specific immunotherapies [@problem_id:5039667] [@problem_id:5039637].

#### Tumor Preparation: Fragments versus Single Cells

The preparation of the initial tumor tissue for implantation is another critical decision. The two main approaches are mechanical mincing to produce small, intact tumor fragments, and enzymatic dissociation to create a single-cell suspension. The choice between them involves a trade-off that depends on the experimental goal [@problem_id:5039638].

*   **Mechanical Mincing (Fragments):** This gentle method best preserves the tumor's native architecture, including the extracellular matrix and the spatial relationships between tumor cells and stromal cells (e.g., [cancer-associated fibroblasts](@entry_id:187462)). This approach maximizes the retention and viability of all cellular components, especially the more fragile stromal and immune cells. It is the preferred method when the integrity of the TME is paramount, such as when studying therapies that target stromal components or [angiogenesis](@entry_id:149600).
*   **Enzymatic Dissociation (Single Cells):** This harsher process uses enzymes like collagenase to break down the ECM and create a suspension of individual cells. While this disrupts the native TME, it can be useful for specific applications. The enzymatic digestion process can differentially affect the viability of various cell types, often leading to a relative enrichment of the more robust epithelial tumor cells compared to stromal and immune cells. This method is advantageous for experiments focused on cell-intrinsic properties, such as in vivo CRISPR screens, where maximizing the purity of the target tumor cell population is desirable to reduce confounding signals from the microenvironment [@problem_id:5039638].

#### Implantation Site: Subcutaneous versus Orthotopic

The anatomical location where the tumor is implanted has a profound influence on its subsequent biological behavior [@problem_id:5039658].

*   **Subcutaneous Implantation:** This is the most common and technically simplest method, involving the placement of tumor tissue under the skin of the mouse's flank. Tumors growing in this site are easily accessible for measurement with calipers, facilitating straightforward assessment of tumor [growth kinetics](@entry_id:189826). However, the subcutaneous space is an **ectopic** (foreign) environment for most cancers (e.g., pancreatic, lung, colon). It provides a generic stromal support that lacks the organ-specific cues of the tumor's native environment. Consequently, subcutaneous tumors often exhibit immature vasculature, high levels of necrosis, and, most importantly, they very rarely invade locally or metastasize spontaneously.
*   **Orthotopic Implantation:** This method involves implanting the tumor tissue into its corresponding organ of origin in the mouse (e.g., a human pancreatic tumor into the mouse pancreas). This approach is technically more demanding but provides a microenvironment that far more faithfully recapitulates the clinical scenario. The tumor interacts with organ-specific stromal cells, ECM, and physiological cues. This "home-field advantage" often results in more clinically relevant growth patterns, more mature and organ-appropriate vascularization, and, crucially, a much higher propensity for local invasion and **spontaneous, organotropic metastasis**. The ability to access native lymphatic and venous drainage pathways from the orthotopic site is essential for modeling the full metastatic cascade, a feature that is almost entirely absent in subcutaneous models [@problem_id:5039658].

### The Evolving Nature of PDX Models: Passaging and Adaptation

A PDX is not a static entity. Once established from a patient ($P0$), it is typically expanded by serially transplanting the tumor from one mouse to another ($P1$, $P2$, $P3$, etc.). This process, known as **passaging**, is essential for generating sufficient cohorts of animals for drug testing, but it also drives the evolution of the tumor, potentially causing it to diverge from the original patient cancer over time [@problem_id:5039647].

This evolution is governed by two fundamental forces of population genetics:

1.  **Clonal Selection:** The murine microenvironment is a new habitat for the human tumor cells. It presents a different set of [selective pressures](@entry_id:175478), including different growth factors, cytokines, and ECM components. Tumor subclones that are better adapted to interacting with and exploiting these murine signals will have a proliferative advantage and will increase in frequency over successive passages.
2.  **Genetic Drift:** Each passage involves transplanting a small inoculum of cells (a **bottleneck**) from a large tumor. This random sampling can cause stochastic fluctuations in the frequencies of different subclones, a phenomenon known as genetic drift. Drift is particularly powerful when the bottleneck size is small, and it can lead to the random loss of subclones, regardless of their fitness.

A key driver of this adaptation is the progressive replacement of the original human stroma with host-derived murine stromal and vascular cells—a process sometimes called **murinization**. While the tumor epithelial cells remain human, the supporting microenvironment becomes a human-mouse chimera. This has critical implications for testing therapies that target the TME [@problem_id:5039615]. For instance, consider a species-specific antibody like **bevacizumab**, which neutralizes human Vascular Endothelial Growth Factor (VEGF) but not murine VEGF. In an early-passage PDX ($P0$), where a significant fraction of the stroma is still human, bevacizumab can effectively block the angiogenic signal. However, as the PDX is passaged, the human stroma is replaced by murine stroma, which produces murine VEGF. This murine VEGF, which is resistant to bevacizumab, becomes an increasingly dominant driver of [angiogenesis](@entry_id:149600). As a result, the efficacy of bevacizumab systematically decreases with increasing passage number. The same principle applies to therapies targeting human stromal cells (e.g., an antibody against human Fibroblast Activation Protein, FAP); as the human fibroblast population declines with passaging, the therapy loses its target and its efficacy diminishes. This underscores the critical importance of using early-passage PDX models, whenever possible, for evaluating therapies that interact with the stromal compartment [@problem_id:5039615].

### Translational Challenges and Limitations of PDX Models

Despite their high fidelity, PDX models have intrinsic limitations rooted in the **[species barrier](@entry_id:198244)** between human and mouse. A sophisticated understanding of these limitations is essential for the correct interpretation of experimental results and their translation to the clinic [@problem_id:5039641].

#### Stroma and Cytokine Mismatch

As discussed, the chimeric nature of the PDX microenvironment is a major confounder. A therapeutic agent may be designed to target a protein on human stromal or immune cells. If that agent does not cross-react with the mouse equivalent, it will appear inactive in a PDX model simply because its target is absent. For example, a human-specific antibody against the receptor **CSF1R** on macrophages is intended to deplete [tumor-associated macrophages](@entry_id:202789) (TAMs). In a PDX, the TAMs are predominantly of mouse origin. The antibody will not bind, and the model will fail to show any anti-tumor effect that depends on TAM depletion. Consequently, the potential efficacy of the drug will be underestimated [@problem_id:5039641]. Similarly, the lack of a human immune system means that standard PDX models in mice like NSG cannot predict [immune-related adverse events](@entry_id:181506), such as **[cytokine release syndrome](@entry_id:196982) (CRS)**, which arise from the [hyperactivation](@entry_id:184192) of human immune cells.

#### Pharmacokinetic Mismatch

The way an organism absorbs, distributes, metabolizes, and excretes a drug—its **pharmacokinetics (PK)**—can differ dramatically between mice and humans.

For **biologics** like monoclonal antibodies, clearance often scales with body weight according to an **allometric relationship**, where clearance ($CL$) is proportional to body weight ($W$) raised to a power of approximately $0.75$ ($CL \propto W^{0.75}$). A consequence of this relationship is that, for a given mg/kg dose, the total drug exposure (Area Under the Curve, or AUC) is significantly lower in a small animal like a mouse than in a human. A 70 kg human may have an AUC that is 7- to 8-fold higher than a 20 g mouse receiving the same mg/kg dose. This means that a lack of efficacy observed in a mouse study may simply reflect insufficient drug exposure, and clinical activity may still be possible at the higher exposures achieved in humans [@problem_id:5039641].

For **small molecules**, metabolism is often the primary driver of PK differences. The repertoire and activity of drug-metabolizing enzymes, particularly the **cytochrome P450 (CYP)** family, are species-specific. This is especially problematic for **prodrugs**, which require metabolic bioactivation to become effective. A prodrug may be rapidly activated in mice but slowly in humans, or vice versa. If mouse enzymes are much more efficient at creating the active metabolite, the mouse may experience a much higher exposure to the active drug than a human at the same mg/kg dose. This can lead to the observation of toxicities in mice (e.g., hepatotoxicity) that would not occur at the lower, clinically relevant exposures in humans, potentially causing a promising drug candidate to be incorrectly terminated [@problem_id:5039641]. These species-specific differences in both pharmacology and pharmacokinetics demand careful consideration when extrapolating findings from PDX models to clinical trial design.